Accelerated Access Collaborative

The Accelerated Access Collaborative (AAC) aims to make the process of getting transformative technologies to patients quicker, cheaper and easier for innovators and the NHS.

The government and its partners, of which the AHSN NENC is one, aim to bring forward patient access to selected, highly beneficial and affordable innovations.

The AAC is currently supporting the rapid uptake of 7 high-potential technology areas with full evidence bases already within the system. These AAC rapid uptake products will enable patients with conditions such as cancer, heart disease and multiple sclerosis to access new treatments faster.

The rapid uptake products are:

  • HeartFlow Analysis for estimating fractional flow reserve from coronary CT angiography – A non-invasive personalised cardiac test that reduces the need for unnecessary procedures [HeartFlow Inc]
  • Placental growth factor (PIGF) based testing for suspected preeclampsia – Two tests for early diagnosis of pre-eclampsia in pregnant women, which if unmonitored, can cause serious complications for mother and baby.

Elecsys immunoassay sFlt-1/PLGF ratio [Roche Diagnostics]

– Triage PlGF test [Quidel Corporation]

  • PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia – Two cost-effective drugs that significantly lower cholesterol.

– alirocumab [Sanofi]

– evolocumab [Amgen]

  • High sensitivity troponin tests for early rule out of myocardial infarction – Two diagnostic tests that detect whether or not a patient is at risk or previously had a heart attack.

– Elecsys Troponin T high-sensitive [Roche Diagnostics]

– ARCHITECT STAT High Sensitive Troponin-I [Abbott Diagnostics]

  • Quantitative faecal immunochemical tests for colorectal cancer – Three diagnostic tests that reduce referrals for patients with suspected colorectal cancer.

– OC Sensor [MAST Diagnostics]

– HM-JACKarc [Alpha Laboratories]

– FOB Gold [Sysmex]

  • Cladribine for treating highly active relapsing-remitting multiple sclerosis in adults – A drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden [Brand name: Mavenclad, Merck]
  • Urolift for lower urinary tract symptoms of benign prostatic hyperplasia – A cost-saving device that relieves painful urinary tract symptoms in men [Teleflex]

Phase Two Documentation

The following documents are required when making an application:

190918 PTF Phase 2 Application Form final

190918 PTF Phase 2 Application Scoring Guide for AHSNs final

190918 PTF Phase 2 Guidance and FAQ final

Pathway Transformation Fund (PTF)

The AHSN Network is supporting the launch of the first phase of the Accelerated Access Collaborative Pathway Transformation Fund (PTF), which was announced by government in July 2017.

Funding through the new PTF will be made available to help NHS organisations integrate the rapid uptake products into everyday practices, supporting an improvement in equality of access and reducing health inequalities that exist regarding diagnosis and disease management. The fund focuses on three of the AAC rapid uptake products (UroLift, placental growth factor-based testing and high-sensitivity troponin testing in an under three-hour protocol.

The PTF can help providers overcome more practical obstacles to deploying these products, such as: training staff on how to use new equipment; pathway redesign and/or business support expertise; providing specialist nurses/clinical staff needed to implement a new part of the procedure; or covering double running costs.

Find out More

For further information on the AAC, click here for NICE guidance and here for NHS England information.   If you would like to know more about AHSN in the NENC contact Stephen Lynn or Rachel Morris.